355 related articles for article (PubMed ID: 2846827)
1. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
Millan MJ; Morris BJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
[TBL] [Abstract][Full Text] [Related]
2. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
3. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical axis level.
Alcaraz C; Vargas ML; Fuente T; Milanés MV
J Pharmacol Exp Ther; 1993 Sep; 266(3):1602-6. PubMed ID: 8396640
[TBL] [Abstract][Full Text] [Related]
4. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
[TBL] [Abstract][Full Text] [Related]
5. Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli.
Millan MJ
J Pharmacol Exp Ther; 1989 Oct; 251(1):334-41. PubMed ID: 2571722
[TBL] [Abstract][Full Text] [Related]
6. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
7. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors.
Stein C; Millan MJ; Shippenberg TS; Peter K; Herz A
J Pharmacol Exp Ther; 1989 Mar; 248(3):1269-75. PubMed ID: 2539460
[TBL] [Abstract][Full Text] [Related]
8. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
10. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
Gistrak MA; Paul D; Hahn EF; Pasternak GW
J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
[TBL] [Abstract][Full Text] [Related]
12. 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. III. Structurally diverse 5-HT1A partial agonists attenuate mu- but not kappa-opioid antinociception in mice and rats.
Millan MJ; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):993-1001. PubMed ID: 1672381
[TBL] [Abstract][Full Text] [Related]
13. Cross-tolerance between mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus.
Garaulet JV; Laorden ML; Milanés MV
J Pharmacol Exp Ther; 1994 Jun; 269(3):993-9. PubMed ID: 8014886
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues.
Capasso A; Di Giannuario A; Loizzo A; Pieretti S; Sagratella S; Sorrentino L
J Pharmacol Exp Ther; 1996 Feb; 276(2):743-51. PubMed ID: 8632345
[TBL] [Abstract][Full Text] [Related]
15. Effect of endothelin-A receptor antagonist on mu, delta and kappa opioid receptor-mediated antinociception in mice.
Bhalla S; Zhang Z; Patterson N; Gulati A
Eur J Pharmacol; 2010 Jun; 635(1-3):62-71. PubMed ID: 20303944
[TBL] [Abstract][Full Text] [Related]
16. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
17. Selective tolerance at mu and kappa opioid receptors modulating norepinephrine release in guinea pig cortex.
Werling LL; McMahon PN; Cox BM
J Pharmacol Exp Ther; 1988 Dec; 247(3):1103-6. PubMed ID: 2849659
[TBL] [Abstract][Full Text] [Related]
18. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
19. The effect of mu and kappa opioid receptor agonists on cAMP level in hippocampus of kainic acid-treated rats.
Dziedzicka-Wasylewska M; Przewłocki R
Pol J Pharmacol; 1995; 47(2):121-6. PubMed ID: 8688884
[TBL] [Abstract][Full Text] [Related]
20. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids.
Kest B; McLemore G; Kao B; Inturrisi CE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1249-55. PubMed ID: 9400000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
